Shield Therapeutics logo

STX - Shield Therapeutics Share Price

86p -2.5  -2.8%

Last Trade - 01/04/20

Sector
Healthcare
Size
Small Cap
Market Cap £103.7m
Enterprise Value £97.2m
Revenue £14.0m
Position in Universe 858th / 1833
Bullish
Bearish
Unlock STX Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

STX Revenue Unlock STX Revenue

Net Income

STX Net Income Unlock STX Revenue

Normalised EPS

STX Normalised EPS Unlock STX Revenue

PE Ratio Range

STX PE Ratio Range Unlock STX Revenue

Dividend Yield Range

STX Dividend Yield Range Unlock STX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
STX EPS Forecasts Unlock STX Revenue
Profile Summary

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company's product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed. It also has a pipeline of over three prescription pharmaceutical assets, including PT20, PT30 and PT40. PT20, which is in Phase II clinical trials, is used as a treatment for hypophosphatemia. PT30, which indicates advanced intravenous (IV) iron formulation, is in pre-clinical stage. Its PT40, which indicates generic IV iron formulation, is in pre-clinical trials. Feraccru, which indicates IDA in chronic kidney disease (CKD) and inflammatory bowel disease (IBD), is in Phase III clinical trials. Its other indications for Feraccru are in Phase II clinical trials.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated September 3, 2015
Public Since February 26, 2016
No. of Shareholders: n/a
No. of Employees: 15
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 117,188,657
Free Float (0.0%)
Eligible for
ISAs
SIPPs
STX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for STX
Upcoming Events for STX
Friday 12th June, 2020 Estimate
Shield Therapeutics PLC Annual Shareholders Meeting
Similar to STX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.